What the November 2025 refresh means for your site contracts
A clinical trial contract isn’t where the science happens. It’s where the science waits.
That waiting is what the Accelerated Clinical Trial Agreement (ACTA) was built to reduce. Sponsors and sites start from one pre-negotiated template, funded through the NIH’s Clinical and Translational Science Award program, helping avoid revisiting terms that the parties have already aligned around. As of November 17, 2025, that template changed.
The revised ACTA is the leading edge of a broader refresh. The Investigator-Initiated ACTA, the CRO-ACTA, ACTA Prime, and ACTA CRO Prime all follow through 2026. It’s a moderate revision touching roughly twenty clauses. But “moderate” can be misleading. Several of the changes have meaningful practical implications, and four of them are worth a site’s close attention.
Four ACTA changes that could affect contract negotiations
Insurance minimums are gone.
The old form hardcoded coverage floors — $1 million/$3 million for the institution, $3 million/$5 million for the sponsor. The new form replaces them with insurance “at levels sufficient to support its obligations.” For academic medical centers or public institutions that self-insure, that single edit removes a clause that often requires additional negotiation. Institutions are no longer tied to coverage thresholds that may not align with how they actually carry risk.
The sponsor’s indemnity got broader.
Section 11.1 was restructured and expanded to address a broader range of circumstances, including the sponsor’s material breach, non-compliance with applicable law, negligence, and use of site data and study results. That’s more than housekeeping. The revision provides greater specificity around how responsibility is allocated when harm arises from these circumstances. The result is a clearer framework for assigning risk and responsibility between the parties based on their respective roles and activities.
You get a say if the agreement changes hands.
New language in Section 17.2 gives the institution 30 days to evaluate any party to whom the sponsor assigns the agreement — and the right to terminate, without penalty, if it is not comfortable moving forward. Trials change ownership. Sponsors merge. Programs are acquired. This provision gives institutions an opportunity to assess a new party before continuing the relationship.
Two new sponsor commitments appear in the revised agreement.
Section 1.4 adds a certification that the study, drug, or device has been manufactured and handled in accordance with applicable GMP regulations for human use. Section 16.1 requires sponsors to maintain compliant equipment and promptly notify institutions of recalls or regulatory withdrawals. Both are quality and safety commitments that many parties already expect in practice. The difference is that they are now explicitly in the contract.
There are also several smaller refinements throughout the agreement. The payment trigger simplified to “for the conduct of the Study.” Data-breach notification moved from “immediately” to the more workable “promptly.” Wind-down cooperation softened to “reasonably,” and confidential information held in automatic backups was excluded from return-and-destroy requirements. These changes largely clarify existing expectations rather than alter the underlying relationship.
Reducing contract negotiation delays with ACTA standardization
Here’s what none of this changes: the importance of working from the current version of the agreement. When sites and sponsors are negotiating from different ACTA versions, discussions can end up revisiting terms the standard was designed to streamline. The efficiencies of a common framework depend on both parties operating from the same starting point.
That’s where WCG Contract Intelligence (formerly The Contract Network) can help. Our analysts have already ingested the revised ACTA, mapped every substantive change against the prior form, and updated our negotiation profiles accordingly. Each template change is tied to a corresponding profile position, helping sites approach discussions with a current and informed understanding of the agreement rather than catching up once negotiations begin.
Don’t negotiate the new ACTA blind.
Complete the form to unlock our comprehensive analysis of every substantive change.